Henry Ford Health System to Present Webinar on Positive Clinical Impact of T2 Biosystems’ T2Candida® Panel

LEXINGTON, Mass., May 19, 2017 -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET.

The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR^® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use.

To read more on this free webinar, learn about the continuing education credits offered, or to register, click here.

About George Alangaden MD, FACP, FIDSA

Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute.

Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

About LabRoots

LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
[email protected] 
603-553-5803

Media Contact:
Matthew McKillip, T2 Biosystems
[email protected] 
518-577-3466

Investor Contact:
Tucker Elcock, Teneo Strategy
[email protected] 
212-886-9319